Autoimmune diseases arise when the immune system mistakenly targets and damages the body’s cells and tissues as though they ...

T cells are central mediators of autoimmune disease pathogenesis, yet their functional states are not defined solely by antigen recognition or canonical ...

Annual 2025 reports reveal a jump in fundraising for the 2026 elections. Individuals with accounts in Idaho Sunshine, the state’s campaign finance portal, had to submit annual reports by Jan. 10 ...

A recent study by Vanderbilt Health researchers has revealed a greater, detrimental role for B lymphocytes (B cells) in the ...

Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics ...

Cohort 4 data demonstrated positive safety and efficacy results, including additional clinical benefit observed following ...

The SFDA is the first regulatory authority globally to grant conditional approval for this medication for the treatment of NSCLC ...

Detailed price information for Coya Therapeutics Inc (COYA-Q) from The Globe and Mail including charting and trades.

Coherus Oncology, Inc. ( CHRS) 44th Annual J.P. Morgan Healthcare Conference January 13, 2026 1:30 PM EST Good morning everyone. It's still the morning. Thanks for joining us for another session at ...

Therapies market, valued at USD 16.7 million in 2024, is expected to register robust revenue CAGR of 44.6%.Request free copy of this report: 13, 2026- The growing incidence of autoimmune disorders ...